SLC5A2 and allergic asthma: We demonstrated that SGLT2 inhibitors, empagliflozin and canagliflozin, suppressed HSA-induced mast cell degranulation in vitro in a concentration-dependent manner and showed their therapeutic efficacy against OVA-induced allergic asthma in vivo.